Common Contracts
11 similar null contracts by Atossa Therapeutics, Inc., INVO Bioscience, Inc., Payment Data Systems Inc, others
August 4, 2023 INVO Bioscience, Inc.INVO Bioscience, Inc. • August 8th, 2023 • Surgical & medical instruments & apparatus • New York
INVO Bioscience, Inc.INVO Bioscience, Inc. • July 31st, 2023 • Surgical & medical instruments & apparatus • New York
INVO Bioscience, Inc.INVO Bioscience, Inc. • March 28th, 2023 • Surgical & medical instruments & apparatus • New York
Sphere 3D Corp.Sphere 3D Corp • September 9th, 2021 • Services-computer processing & data preparation • New York
Mr. Steven C. Quay Chief Executive Officer Atossa Therapeutics, Inc.Atossa Therapeutics, Inc. • March 23rd, 2021 • Pharmaceutical preparations • New York
Mr. Steven C. Quay Chief Executive Officer Atossa Therapeutics, Inc.Atossa Therapeutics, Inc. • January 8th, 2021 • Pharmaceutical preparations • New York
Mr. Steven C. Quay Chief Executive Officer Atossa Therapeutics, Inc.Atossa Therapeutics, Inc. • December 21st, 2020 • Pharmaceutical preparations • New York
Mr. Louis A. Hoch Vice-Chairman & Chief Executive Officer Payment Data Systems, Inc.Payment Data Systems Inc • February 13th, 2019 • Functions related to depository banking, nec • New York
Mr. Lei Cao Chairman, CEO and President Sino-Global Shipping America, LtdSino-Global Shipping America, Ltd. • March 12th, 2018 • Arrangement of transportation of freight & cargo • New York
Mr. Steven C. Quay Chief Executive Officer Atossa Genetics, Inc.Atossa Genetics Inc • December 22nd, 2017 • Pharmaceutical preparations • New York
Mr. Louis A. Hoch Vice-Chairman & Chief Executive Officer Payment Data Systems, Inc. 12500 San Pedro, Ste. 120 San Antonio, TX 78216Payment Data Systems Inc • December 22nd, 2017 • Functions related to depository banking, nec • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Payment Data Systems, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), that Maxim shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of common stock (the “Shares”) of the Company, par value $0.001 per share (“Common Stock”). The terms of the Placement and the Shares shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Shares or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Placement, including but not limited to the Purchase
